FDA Clearance Tracker · P970051-S205
Nucleus 24 Cochlear Implant System
Last checked: Nov 20, 2026Latest source record: Jan 10, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Jan 10, 2022
Approved
Time to decision
227 days
Received May 28, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P970051-S205
- Device name
- Nucleus 24 Cochlear Implant System
- Applicant
- Cochlear Americas
- Applicant location
- Lone Tree, CO
- Received
- May 28, 2021
- Decided
- Jan 10, 2022
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P970051
Device type
- Device type
- Implant, cochlear (MCM)
- Device class
- Class III
- Specialty
- Otolaryngology (ENT)
FDA's approval statement
As written in FDA's record.
Approval for the Cochlear Nucleus 24 cochlear implant system. The device is indicated for individuals with unilateral hearing loss who meet the following criteria:1) Individuals 5 years or older who have one ear with a severe to profound sensorineural hearing loss and obtain limited benefit from an appropriately fitted unilateral hearing device and one ear with normal or near normal hearing. a) In the ear to be implanted, a severe to profound sensorineural hearing loss defined as a PTA at 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz of > 80 dB HL; andb) In the contralateral ear, normal or near normal hearing is defined as a PTA at 500 Hz, 1000 Hz, 2000 Hz and 4000 Hz <= 30 dB HL.2) Limited benefit from an appropriately fit unilateral hearing device is defined as a score of less than or equal to 5% on a Consonant Nucleus Consonant (CNC) word test. For individuals between 5 years and 18 years of age, insufficient functional access to sound in the ear to be implanted must be determined by aided speech perception test scores of 10% or less on developmentally appropriate word lists when tested in the ear to be implanted alone.3) It is recommended that prior to cochlear implantation, individuals with SSD have at least two (2) weeks to one (1) month experience wearing appropriately fit Contralateral Routing of Signal (CROS) hearing aid or another suitable hearing device.
Source documents
Other decisions for Cochlear Americas
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260902 · Decided Jul 10, 2026 · 114 days after receipt
Device type: Active Implantable Bone Conduction Hearing System (PFO) · Otolaryngology (ENT)
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.